Predicting Corticosteroid-Free Biologic Remission with Vedolizumab in Crohn's Disease.
暂无分享,去创建一个
Akbar K Waljee | P. Higgins | Ji Zhu | A. Waljee | R. Stidham | Boang Liu | Kay Sauder | Ji Zhu | Shail M Govani | Ryan W Stidham | Peter D R Higgins | K. Sauder | S. Govani | Boang Liu
[1] S. Saini,et al. Systematic review with network meta‐analysis: the efficacy of anti‐TNF agents for the treatment of Crohn's disease , 2014, Alimentary pharmacology & therapeutics.
[2] Jesus Romero,et al. Integrated, reliable and cloud-based personal health record: A scoping review , 2016, ArXiv.
[3] Kristin Stephens,et al. Vedolizumab as induction and maintenance therapy for Crohn's disease. , 2013, The New England journal of medicine.
[4] John T. Chang,et al. The Real-World Effectiveness and Safety of Vedolizumab for Moderate–Severe Crohn’s Disease: Results From the US VICTORY Consortium , 2016, American Journal of Gastroenterology.
[5] B. Flourié,et al. Association Between Low Trough Levels of Vedolizumab During Induction Therapy for Inflammatory Bowel Diseases and Need for Additional Doses Within 6 Months , 2017, Clinical gastroenterology and hepatology : the official clinical practice journal of the American Gastroenterological Association.
[6] S. Saini,et al. Systematic review with network meta‐analysis: the efficacy of anti‐tumour necrosis factor‐alpha agents for the treatment of ulcerative colitis , 2014, Alimentary pharmacology & therapeutics.
[7] S. Vermeire,et al. Antibodies Toward Vedolizumab Appear from the First Infusion Onward and Disappear Over Time , 2017, Inflammatory bowel diseases.
[8] L. Peyrin-Biroulet,et al. JAK inhibition in inflammatory bowel disease , 2017, Expert review of clinical immunology.
[9] E. Loftus. Clinical epidemiology of inflammatory bowel disease: Incidence, prevalence, and environmental influences. , 2004, Gastroenterology.
[10] G. Fiorino,et al. IL-23 Blockade for Crohn s disease: next generation of anti-cytokine therapy , 2017, Expert review of clinical immunology.
[11] W. Sandborn,et al. Population pharmacokinetics‐pharmacodynamics of vedolizumab in patients with ulcerative colitis and Crohn's disease , 2015, Alimentary pharmacology & therapeutics.
[12] Andy Liaw,et al. Classification and Regression by randomForest , 2007 .